Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Hepatoblastoma, drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Metastatic and low-AFP disease.
Long-term effects of cisplatin (hearing, kidney) and doxorubicin (heart).
Rising incidence with extreme prematurity.
Transplant organ availability and lifelong immunosuppression in children.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
FDA approval of sodium thiosulfate (Pedmark) 2022.
A milestone in how this cancer is treated.
Upfront resection for PRETEXT I-II (COG) or cisplatin monotherapy ×4-6 with delayed resection (SIOPEL-3); sodium thiosulfate after each cisplatin dose for otoprotection.
Complete remission at the end of therapy in 79 percent of 62 high-risk patients; complete resection 74 percent; three-year event-free survival 76 percent and overall survival 83 percent.
A milestone in how this cancer is treated.